Unapproved Cell/Tissue Product Enforcement Discretion Ends; How Hard Will US FDA Crack Down?

 
• By Derrick Gingery
Person cracking a nut
Should sponsors expect a flurry of enforcement activity now that the FDA's discretion policy has ended? • Source: Alamy

More from Cell & Gene Therapies

More from Advanced Technologies